Biopharma Clinical And Commercial Outsourcing
Our client would like to speak with multiple decision-makers in the pharma or biotech industries who have significant influence over selecting providers for the outsourcing of tasks involved in clinical development or drug commercialization.
The study will be focusing on the different types of commercial service providers or vendors.
This is a 45-minute web interview. If open to participating, please provide a brief answer to the screener below:
assuming that your company was thinking of selecting a provider for the outsourcing of tasks involved in clinical development or drug commercialization, which of the following best describes your role in the provider selection process? Please select one.
A. I am / would be the final decision maker
b. I am part of a team that makes the decision
c. I am part of a team that makes recommendations to a final decision maker
d. While not part of the decision-making team, i do have a significant influence on the final decision
e. I am the subject matter expert/reviewer but do not have any decision-making authority
f. Not involved in the selection process
please note that we are only interested in your personal point of view and are not seeking confidential information.
Referrals are welcome.
+14 Other ResponsesBiopharma Single-use Tubings & Connectors
We are looking for an expert from biopharmaceutical industry who has first hands-on experience in the field of single-use tubings and connectors procurement.
The expert should be able to provide us with insights on the above mentioned product categories.
Please contact us if you have relevant experience in this field and we will share the questions with you.
Thanks!
+22 Other ResponsesSupply Chain Best Practices In Biopharma
I am writing on behalf of a consulting firm that conducts expert interviews in support of industry-wide studies for many of the world's fortune 1000 companies. We help businesses answer questions by engaging with the world’s most relevant experts. So far we have delivered over 1000 studies with input from over 18,000 individuals. We are an authorized zintro partner.
For a current study, we are seeking to speak with experts who can share insights around the impact that potential us tax system changes might have on the bio-pharma manufacturing sector. More specifically, our client assumes that the new trump administration in the us will incur major changes in tax systems (e.G. Corporate tax cut, tax exemption over export products, etc.). We are seeking to understand what would be the key changes, resulting from that, or key impacts over bio-pharma in-house or outsourcing strategy. Please note that we would only consider us- or europe-based experts with recent experience and who can provide shared learnings from one or more of the following companies:
1st priority: j&j, bms, pfizer, abbvie, amgen
2nd priority: roche/genentech, novartis, astrazeneca
please note that we are only interested in your personal point of view and expert insight and are not seeking any confidential information.
We would welcome any referrals to other relevant experts as well.
Best regards,
vlady
+9 Other Responses
